Biocryst Pharmaceuticals Stock Investor Sentiment

BCRX Stock  USD 7.50  0.01  0.13%   
Slightly above 59% of all BioCryst Pharmaceuticals' investors are looking to take a long position. The analysis of the overall investor sentiment regarding BioCryst Pharmaceuticals suggests that some traders are interested. BioCryst Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, BioCryst Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.

Panic Vs Confidence

59

 
Panic
 
Confidence
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use BioCryst Pharmaceuticals' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward BioCryst Pharmaceuticals.

BioCryst Historical Sentiment

Although BioCryst Pharmaceuticals' investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding BioCryst, such as negative comments on social media and news outlets, may cause fear in the market and push BioCryst Pharmaceuticals' investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of BioCryst.
  
3 days ago at simplywall.st         
Market Sentiment Around Loss-Making BioCryst Pharmaceuticals, Inc.
Simply Wall St News at Macroaxis
few days ago at finance.yahoo.com         
BioCryst Pharmaceuticals, Inc. Is Expected To Breakeven In The Near Future
Yahoo News
six days ago at news.google.com         
Principal Financial Group Inc. Buys 375,890 Shares of BioCryst Pharmaceuticals, Inc. - MarketBeat
Google News at Macroaxis
over a week ago at thelincolnianonline.com         
Segall Bryant Hamill LLC Sells 36,105 Shares of BioCryst Pharmaceuticals, Inc.
news
over a week ago at news.google.com         
BioCryst Pharmaceuticals, Inc. Stock Holdings Increased by Counterweight Ventures LLC - MarketBeat
Google News at Macroaxis
over a week ago at finance.yahoo.com         
BioCryst Launches ORLADEYO in Ireland
Yahoo News
over a week ago at globenewswire.com         
BioCryst Launches ORLADEYO in Ireland
Macroaxis News: globenewswire.com
over a week ago at news.google.com         
BioCrysts ORLADEYO Becomes First Oral HAE Treatment Approved in Ireland BCRX Stock News - StockTitan
Google News at Macroaxis
over two weeks ago at investing.com         
Earnings call Clearside Biomedical reports progress in AMD treatment
Investing News at Macroaxis
over two weeks ago at investing.com         
BioCrysts SWOT analysis stock outlook amid orladeyo success, pipeline shifts
Investing News at Macroaxis
over two weeks ago at www.macroaxis.com         
Acquisition by Jon Stonehouse of 10000 shares of BioCryst Pharmaceuticals subject to Rule 16b-3
Macroaxis News
over three weeks ago at gurufocus.com         
Vanguard Group Incs Strategic Acquisition in BioCryst Pharmaceuticals Inc
Gurufocus Stories at Macroaxis
over three weeks ago at bizjournals.com         
Drugmaker eyes billion-dollar pill
bizjournals News
over three weeks ago at investing.com         
Earnings call Royalty Pharma reports robust Q3 growth, raises guidance
Investing News at Macroaxis
over three weeks ago at globenewswire.com         
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635
Macroaxis News: globenewswire.com
Far too much social signal, news, headlines, and media speculation about BioCryst Pharmaceuticals that are available to investors today. That information is available publicly through BioCryst media outlets and privately through word of mouth or via BioCryst internal channels. However, regardless of the origin, that massive amount of BioCryst data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of BioCryst Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of BioCryst Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to BioCryst Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive BioCryst Pharmaceuticals alpha.

BioCryst Pharmaceuticals Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Disposition of 100000 shares by Jon Stonehouse of BioCryst Pharmaceuticals at 10.38 subject to Rule 16b-3
09/24/2024
2
BioCryst awarded 69M influenza treatment contract from U.S. HHS
09/30/2024
3
BioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting ORLADEYO
10/14/2024
4
BioCryst earnings matched, revenue topped estimates
11/04/2024
5
BioCryst Pharmaceuticals Inc Q3 2024 Earnings Call Highlights Strong ORLADEYO Growth ...
11/05/2024
6
Earnings call Royalty Pharma reports robust Q3 growth, raises guidance
11/06/2024
7
Acquisition by Jon Stonehouse of 10000 shares of BioCryst Pharmaceuticals subject to Rule 16b-3
11/08/2024
8
BioCrysts SWOT analysis stock outlook amid orladeyo success, pipeline shifts
11/12/2024
9
BioCryst Launches ORLADEYO in Ireland
11/18/2024
10
Segall Bryant Hamill LLC Sells 36,105 Shares of BioCryst Pharmaceuticals, Inc.
11/21/2024
11
Market Sentiment Around Loss-Making BioCryst Pharmaceuticals, Inc.
11/27/2024

Additional Tools for BioCryst Stock Analysis

When running BioCryst Pharmaceuticals' price analysis, check to measure BioCryst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioCryst Pharmaceuticals is operating at the current time. Most of BioCryst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of BioCryst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioCryst Pharmaceuticals' price. Additionally, you may evaluate how the addition of BioCryst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.